AKEBIA THERAPEUTICS INC. - COMMON STOCK

Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa

03 Apr 2025 08:00:01 By Nasdaq GlobeNewswire

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Apr 2025 16:05:00 By Nasdaq GlobeNewswire

Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

25 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

19 Mar 2025 22:17:53 By Nasdaq GlobeNewswire

Akebia Therapeutics Announces Proposed Public Offering of Common Stock

19 Mar 2025 16:01:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: AKEBIA THERAPEUTICS INC. - COMMON STOCK

19 Mar 2025 10:01:40 By NetDania Notify

NetDania - New 12 months High: AKEBIA THERAPEUTICS INC. - COMMON STOCK

18 Mar 2025 13:14:28 By NetDania Notify

Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update

13 Mar 2025 07:00:00 By Nasdaq GlobeNewswire

Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights

06 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Mar 2025 16:05:00 By Nasdaq GlobeNewswire

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Feb 2025 16:05:00 By Nasdaq GlobeNewswire